Toronto, ON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) today announced that its wholly-owned digital health platform and marketplace, Rocket Doctor Inc., is receiving advisory services and funding of up to $75,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop secure communications functionality, and funding of up to $25,000 from the CanExport SMEs program to accelerate produ ...

Rocket Doctor has signed contracts and is in credentialing with six major insurance companies across Medicare Advantage, Commercial, and Medicaid Managed Care.Coverage estimated to include more than 7 million members across California and New York State. Patients covered under these plans can now access in-network physicians using Rocket Doctor’s physician-led, AI-powered digital health platform and marketplace, which supports comprehensive urgent care, primary care, mental health, chronic disease managemen ...

Vancouver, BC, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) announces that, due to the Canada Postal Strike, there is a delay in the mailing of the Company’s proxy circular and related documents pertaining to the Company’s Annual General Meeting (the “Meeting”) of the shareholders to be held on Wednesday, October 22, 2025 at the hour of 10:00 a.m. (Pacific Time) at the offices of McMillan LLP, Suite 1500 – 1055 West Georgia Street, Vanc ...

Core Insights - Rocket Doctor AI Inc. has formed a partnership with the Town of Bruderheim, Alberta, to provide virtual healthcare services fully covered by Alberta Health, marking its first collaboration with a Canadian municipality [1][4] - The partnership aims to enhance access to essential healthcare services for Bruderheim residents, addressing challenges faced by rural communities such as staffing shortages and geographic isolation [2][3] Group 1: Partnership Details - The partnership officially launches on September 15, 2025, and will automatically renew on July 10, 2026, for subsequent one-year periods under identical terms [1][7] - Bruderheim residents will have access to a physician-led platform for video and audio appointments with licensed Alberta medical professionals, covering services like urgent care, chronic disease management, preventive health, and comprehensive primary care [2][7] Group 2: Healthcare Challenges - Rural communities in Canada, including Bruderheim, face significant healthcare challenges, including limited access due to staffing shortages, long travel times, and higher health risks [3][4] - The Government of Alberta has recognized these disparities and introduced initiatives like the Rural Health Action Plan (2024–2027) to improve healthcare access in rural areas [4] Group 3: Company Growth and Mission - Rocket Doctor AI has reported strong growth in Alberta, serving over 71,000 Albertans, with 35% from communities with populations under 25,000 [5] - The company aims to bridge gaps in rural healthcare delivery through innovative technology, emphasizing its commitment to partnering with public healthcare systems [5][11]

Core Insights - Mobile-health Network Solutions (MNDR) has secured a strategic investment of US$900,000 from Indopacific Health Investment Corporation to enhance its growth strategy and market entry in Indonesia [1][3] - The investment follows an earlier subscription of US$150,000 in May 2025, bringing Indopacific's total investment in MNDR to US$1.05 million [3] - The funds will primarily be allocated for the acquisition of Lifepack, a digital pharmacy platform in Indonesia, and to support broader market initiatives across Southeast Asia [3][4] Investment Details - The share purchase was executed under a Securities Purchase Agreement dated September 10, 2025, with shares priced at US$1.80 each [2] - The transaction includes customary closing conditions and lock-up provisions in accordance with Nasdaq requirements [2] Company Overview - Mobile-health Network Solutions is an AI-powered digital health platform based in Singapore, with operations across Southeast Asia and plans to expand into the US [5] - The company focuses on providing telemedicine, AI-driven health tools, and virtual clinic infrastructure to enhance healthcare accessibility [5]

Core Insights - Profusa, Inc. is set to launch an AI-driven physician portal in early 2026 within the European Economic Area (EEA), integrating its Lumee™ oxygen monitoring technology with NVIDIA's NeMo for enhanced clinical workflows [1][4] - The company aims to provide real-time biochemistry data to improve healthcare outcomes, linking therapeutic decisions with immediate biochemical changes [2][4] - The portal will facilitate remote patient monitoring and enhance the accuracy of personalized sensor data by connecting with electronic medical records (EMR) [1][4] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors for continuous monitoring of biochemistry [5] - The company is led by experienced management and a scientific team, aiming to deliver affordable and long-lasting biosensors for personal and medical use [5] Technology and Features - The physician portal will translate raw optical signals into reliable biometrics, providing actionable clinical insights rather than just dashboards [3][4] - Key features of the portal include integration with EMRs, remote physiologic monitoring, and a longitudinal health data graph that combines various health data sources [7]

Summary of Tempus AI FY Conference Call (September 08, 2025) Company Overview - **Company**: Tempus AI (NasdaqGS:TEM) - **Industry**: Genomics and Data Analytics in Healthcare Key Points Financial Performance - **Q2 Growth**: - Genomics business experienced a growth acceleration from 20% year-over-year in Q1 to 26% in Q2 [2] - Genomics revenue exceeded 30% growth due to reimbursement tailwinds [2] - Adjusted EBITDA improved by approximately $10 million quarter-over-quarter, with expectations to achieve positive adjusted EBITDA in 2025 [2] Business Expansion and Strategy - **Revenue Milestone**: Company is approaching $1.3 billion in revenue, with both main business segments growing at around 30% [3] - **Acquisition of Amri**: - Expected to enhance growth rates, particularly in rare diseases and pediatrics [5] - Q2 growth for Amri was over 30%, with half attributed to market share gains [14] - **Portfolio Expansion**: Focus on expanding beyond oncology into areas like rare diseases, with expectations of positive reimbursement trends [5] Market Dynamics - **Oncology Landscape**: - There are nearly 15,000 oncologists in the U.S., indicating a significant market for holistic solutions [4] - The company believes that the largest players in minimal residual disease (MRD) will also dominate treatment selection [4] - **Reimbursement Trends**: - Positive trends in securing commercial payer reimbursement, although the landscape remains fragmented [9] - MRD tests currently lack reimbursement, with expectations for improvement by the end of the year [10] Data Infrastructure and Technology - **Data Investments**: - Tempus has invested heavily in building a robust technology stack, employing around 700 software engineers [18] - The company has developed proprietary tools to make healthcare data actionable for clients [19] - **Foundation Model**: - A significant project involving over 350 petabytes of data and 1,800 GPUs aimed at generating insights for oncology [28] - The model is expected to enhance the personalization and contextualization of tests, improving clinical decision-making [29] AI and Healthcare - **AI Integration**: - The company is a leader in applying AI to diagnostics, with several FDA-approved algorithms [37] - There is a recognized need for reimbursement mechanisms for AI-driven solutions in healthcare [36] - **Future Outlook**: - AI is anticipated to have a transformative impact on healthcare, with significant potential for cost savings and improved outcomes [61] Challenges and Considerations - **Market Competition**: - The company faces competition in securing reimbursement and market share, particularly in the MRD space [10] - **Long-term Growth**: - While current growth rates are strong, the sustainability of share gains from competitors is uncertain [14] Additional Insights - **Client Engagement**: - The company has established long-term contracts with major pharmaceutical clients, indicating strong demand for its data services [33] - **Product Differentiation**: - Tempus aims to differentiate its genomic tests through integrated data insights, enhancing the value proposition for physicians [27] This summary encapsulates the key insights and developments discussed during the Tempus AI FY Conference Call, highlighting the company's growth trajectory, strategic initiatives, and the evolving landscape of genomics and data analytics in healthcare.

Company Overview - Mobile-health Network Solutions (MNDR) is a leading AI-powered digital healthcare platform provider headquartered in Singapore, with operations across Southeast Asia and expanding into the US [9] - Jospong Group of Companies is a diversified Ghanaian holding company with over 70 subsidiaries, operating in sectors such as waste management, banking, healthcare, insurance, logistics, and real estate [10][11] Partnership Details - MNDR and Jospong have signed a Memorandum of Understanding (MOU) to form a joint venture aimed at launching and operating MNDR's AI-powered digital health platform in Ghana [1][2] - The partnership combines MNDR's telehealth and AI-driven technology with Jospong's local market knowledge and capital resources, designed to accelerate the platform's market entry [2] Market Context - Ghana, with a population exceeding 33 million, is identified as a key market for healthcare innovation, benefiting from a similar institutional framework to other Commonwealth nations [3] - The joint venture aims to address the significant need for accessible healthcare solutions in Ghana, particularly in rural areas, by connecting patients with medical professionals through remote consultations [4] Strategic Goals - The collaboration is expected to enhance healthcare affordability, accessibility, and availability across Africa, serving as a blueprint for future regional expansion [6] - Both companies are committed to a swift and comprehensive due diligence process to finalize the joint venture agreement [6]

Financial Performance - Alcidion achieved a record FY25 revenue of $40.8 million, a 10% increase compared to the prior corresponding period (pcp)[31] - The company's Annual Recurring Revenue (ARR) as of June 30, 2025, reached $28.5 million, up 31% from the previous year[31] - Underlying EBITDA for FY25 was $5.1 million, a significant improvement from the $3.4 million loss in FY24[31] - Alcidion reported positive operating cash flow of $5.8 million in FY25, a substantial turnaround from the $7.1 million loss in FY24[31] - The company's balance sheet shows a strong cash position of $17.7 million as of June 2025[15] Contract Wins and Growth Drivers - New Total Contract Value (TCV) reached $73.8 million, a 109% increase compared to pcp, driven by a milestone $39 million+ EPR contract[31] - Alcidion secured a significant contract with North Cumbria NHS Trust (UK) for a new EPR solution valued at over $39.0 million over 10 years[31, 55] - The company has $34 million in contracted revenue to be recognized in FY26, providing a solid foundation for future growth[31] Strategic Focus and Outlook - Alcidion is focusing on Flow & EPR opportunities, module expansion, adjacent markets, and geographical expansion to drive growth[31] - The company is targeting to be EBITDA positive and deliver positive operating cash flow in FY26[76] - Alcidion is exploring entry into new geographies, including Canada, Saudi Arabia, and UAE[77]

Financial Data and Key Metrics Changes - The company reported no financings completed in Q2 2025, leading to limited revenue generation, primarily from Pat Invest as operations scale [5][6] - Cash utilization for the first six months of 2025 was $3.4 million, with expectations to close financings in February 2025 to reduce or eliminate cash usage [7] Business Line Data and Key Metrics Changes - The company is focusing on incubating more companies to offset operating expenses with financings, balancing equity generation and fee income [6] - The current revenue from launching more developed companies is intended to cover cash operations [6] Market Data and Key Metrics Changes - The company noted a significant investor hesitation towards deep tech and life science investments, which have been underperforming in the market [9][10] - There is a growing interest in profitable, early-stage companies with revenue momentum, which are highly valued in the current market [13] Company Strategy and Development Direction - The company aims to expand its product mix to include profitable companies with revenue momentum, moving beyond just life sciences [14] - A new prospectus was filed for a profitable beverage company, Buddha Juice, indicating a shift towards diverse investment opportunities [15][16] - The company is also focusing on metabolic health as a significant opportunity, particularly with GLP-1 drugs, which represent a large market potential [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the public venture model, highlighting a shift away from private equity and traditional venture capital [17][18] - The company is preparing to spin off PatentVest as an independent public company, which is expected to create additional value for shareholders [50][51] Other Important Information - The company is actively expanding its investor community and has formed a partnership with Koretsu, one of the largest angel groups, to facilitate more deals [31][36] - The emergence of AI is seen as a transformative factor in IP law, which the company is leveraging through its law firm, PatentVest [48][49] Q&A Session Summary Question: Are there vulture opportunities in your core life science market? - Management acknowledged that tough market conditions often lead to better opportunities, with current valuations being reasonable for potential investments [65][66] Question: What's the plan to increase volume and liquidity for portfolio companies? - The focus is on having a correct narrative and adjusting business models to reflect the current environment, with an emphasis on near-term inflection points [71][72] Question: What is the plan for the holding company's assets and potential distributions? - The company plans to distribute equity as much as possible, with a focus on timing distributions around positive news for portfolio companies [83][86]